Related Experiment Video

Updated: Dec 8, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.0K

Epigenetic Dysregulation in Advanced Kidney Cancer: Opportunities for Therapeutic Interventions

Austin Goldsamt1, Nur P Damayanti2, Filomena De Nigris3

  • 1From the Department of Medicine, University at Buffalo, Buffalo, NY.

Cancer Journal (Sudbury, Mass.)
|September 18, 2020
PubMed

Insights

Advanced renal cell carcinoma (RCC) epigenome research reveals new therapeutic targets. Epigenetic modifications influence key cancer pathways, offering potential biomarkers for immunotherapy response.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Epigenetic alterations, including DNA methylation and histone acetylation, are crucial in advanced renal cell carcinoma (RCC) pathogenesis.
  • These modifications regulate gene expression, impacting critical oncogenic signaling pathways like WNT-β-catenin, VHL-HIF, and epithelial-mesenchymal transition.

Purpose of the Study:

  • To explore the complex epigenome of advanced RCC for novel pharmaceutical strategies.
  • To identify new therapeutic targets and biomarkers for treatment interventions in RCC.

Main Methods:

  • Analysis of epigenetic modifications (DNA methylation, histone acetylation) in RCC.
  • Investigation of the role of histone modifier genes in RCC pathogenesis and immunotherapy response.
  • Examination of epigenetic changes in the tumor microenvironment.

Main Results:

  • Epigenetic changes significantly modulate oncogenic signaling pathways in RCC.
  • Alterations in histone modifier genes may serve as biomarkers for predicting immunotherapy response.
  • The tumor microenvironment's epigenetics influences response to targeted therapies.

Conclusions:

  • Understanding RCC epigenetics can drive the development of novel epigenomic-based therapies.
  • Targeting epigenetic mechanisms and combining them with agents like histone deacetylase inhibitors shows therapeutic promise.
  • RCC is a valuable model for studying epigenetics in the tumor microenvironment and its impact on treatment efficacy.

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.3K
Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression06:29

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Published on: January 31, 2025

1.0K

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
243
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.5K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
398
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.7K